CCAR2 and colorectal carcinoma: Loss of CCAR2 resulted in genome-wide dysregulation of active chromatin marks, alterations in the active enhancer landscape, and downregulation of gene expression programs involved in CRC progression and metastasis, such as the Wnt/β-catenin pathway and epithelial-mesenchymal transition.